Bristol-Myers wins US Opdivo approval three months early

The US FDA granted accelerated approval for Bristol-Myers Squibb's programmed cell death-1 (PD-1) inhibitor Opdivo (nivolumab) for the treatment of advanced melanoma more than three months earlier than expected.